Patents by Inventor Brandon Higgs
Brandon Higgs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240150469Abstract: Provided herein are methods of treating B7-H1-expressing tumors comprising administering an effective amount of MEDI4736 or an antigen-binding fragment thereof.Type: ApplicationFiled: October 20, 2023Publication date: May 9, 2024Inventors: Rajest Narwal, David Fairman, Paul Robbins, Meina Liang, Amy Schneider, Carlos Chavez, Carina Herl, Min Pak, Hong Lu, Marlon Rebelatto, Keith Steele, AnnMarie Boutrin, Li Shi, SHENGYAN HONG, Brandon Higgs, Lorin Roskos
-
Patent number: 11827706Abstract: Provided herein are methods of treating B7-H1-expressing tumors comprising administering an effective amount of MEDI4736 or an antigen-binding fragment thereof.Type: GrantFiled: October 16, 2020Date of Patent: November 28, 2023Inventors: Rajesh Narwal, David Fairman, Paul Robbins, Meina Liang, Amy Schneider, Carlos Chavez, Carina Herl, Min Pak, Hong Lu, Marlon Rebelatto, Keith Steele, Anmarie Boutrin, Li Shi, Shengyan Hong, Brandon Higgs, Lorin Roskos
-
Publication number: 20220373539Abstract: The present invention relates to the use of components of the IL23 pathway as biomarkers, e.g., IL22, LCN2 and combinations thereof, to stratify or identify populations of patients suffering from IL23-mediated diseases (e.g., Crohn's disease) responsive to treatment with an anti-IL23 antagonist (including, e.g., anti-IL23 antibodies or antigen-binding fragments thereof). Levels of IL23 pathway biomarkers above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent (e.g., an anti-IL23 antibody), (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent.Type: ApplicationFiled: May 24, 2021Publication date: November 24, 2022Inventors: Robert W. Georgantas, III, Chris Morehouse, Brandon Higgs, Koustubh Ranade, Katie Streicher, William Rees, Meina Liang, Raffaella Faggioni, Jing Li, Inna Vainshtein, Yen-Wah Lee, Jingjing Chen, Robert A. Gasser, JR.
-
Publication number: 20220144935Abstract: The present invention relates to the use of the Chemokine (C—C motif) ligand 20 (CCL20) as a biomarker to stratify or identify populations of patients suffering from interleukin-23 (IL23)-mediated diseases (e.g., Crohn's disease) responsive to treatment with an, anti-IL23 antagonist (including, e.g., anti-IL23 antibodies). Levels of CCL20 above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent, (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent. CCL20 can be used in combination with other IL23 pathway biomarkers such as IL22 and/or lipocalin-2 (LCN2).Type: ApplicationFiled: November 29, 2021Publication date: May 12, 2022Inventors: Robert W. Georgantas, III, Chris Morehouse, Brandon Higgs, Koustubh Ranade, Katie Streicher, William Rees, Meina Liang, Raffaella Faggioni, Jing Li, Inna Vainshtein, Yen-Wah Lee, Jingjing Chen, Robert A. Gasser, JR.
-
Patent number: 11220541Abstract: The present invention relates to the use of the Chemokine (C—C motif) ligand 20 (CCL20) as a biomarker to stratify or identify populations of patients suffering from interleukin-23 (IL23)-mediated diseases (e.g., Crohn's disease) responsive to treatment with an, anti-IL23 antagonist (including, e.g., anti-IL23 antibodies). Levels of CCL20 above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent, (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent. CCL20 can be used in combination with other IL23 pathway biomarkers such as IL22 and/or lipocalin-2 (LCN2).Type: GrantFiled: December 16, 2016Date of Patent: January 11, 2022Assignees: AMGEN INC., MEDIMMUNE, LLCInventors: Robert W. Georgantas, III, Chris Morehouse, Brandon Higgs, Koustubh Ranade, Katie Streicher, William Rees, Meina Liang, Raffaella Faggioni, Jing Li, Inna Vainshtein, Yen-Wah Lee, Jingjing Chen, Robert A. Gasser, Jr.
-
Publication number: 20210171639Abstract: Provided herein are methods of treating B7-H1-expressing tumors comprising administering an effective amount of MEDI4736 or an antigen-binding fragment thereof.Type: ApplicationFiled: October 16, 2020Publication date: June 10, 2021Inventors: RAJESH NARWAL, DAVID FAIRMAN, PAUL ROBBINS, MEINA LIANG, AMY SCHNEIDER, CARLOS CHAVEZ, CARINA HERL, MIN PAK, HONG LU, MARLON REBELATTO, KEITH STEELE, ANMARIE BOUTRIN, LI SHI, SHENGYAN HONG, BRANDON HIGGS, LORIN ROSKOS
-
Patent number: 11016099Abstract: The present invention relates to the use of components of the IL23 pathway as biomarkers, e.g., IL22, LCN2 and combinations thereof, to stratify or identify populations of patients suffering from IL23-mediated diseases (e.g., Crohn's disease) responsive to treatment with an anti-IL23 antagonist (including, e.g., anti-IL23 antibodies or antigen-binding fragments thereof). Levels of IL23 pathway biomarkers above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent (e.g., an ant-IL23 antibody), (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent.Type: GrantFiled: September 16, 2016Date of Patent: May 25, 2021Assignees: AMGEN INC., MEDIMMUNE, LLCInventors: Robert W. Georgantas, III, Chris Morehouse, Brandon Higgs, Koustubh Ranade, Katie Streicher, William Rees, Meina Liang, Raffaella Faggioni, Jing Li, Inna Vainshtein, Yen-Wah Lee, Jingjing Chen, Robert A. Gasser, Jr.
-
Patent number: 10829557Abstract: Provided herein are methods of treating B7-H1-expressing tumors comprising administering an effective amount of MEDI4736 or an antigen-binding fragment thereof.Type: GrantFiled: May 21, 2019Date of Patent: November 10, 2020Assignee: MEDIMMUNE LIMITEDInventors: Rajesh Narwal, David Fairman, Paul Robbins, Meina Liang, Amy Schneider, Carlos Chavez, Carina Herl, Min Pak, Hong Lu, Marlon Rebelatto, Keith Steele, Anmarie Boutrin, Li Shi, Shengyan Hong, Brandon Higgs, Lorin Roskos
-
Publication number: 20200262907Abstract: The present invention relates to the use of the Chemokine (C—C motif) ligand 20 (CCL20) as a biomarker to stratify or identify populations of patients suffering from interleukin-23 (IL23)-mediated diseases (e.g., Crohn's disease) responsive to treatment with an, anti-IL23 antagonist (including, e.g., anti-IL23 antibodies). Levels of CCL20 above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent, (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent. CCL20 can be used in combination with other IL23 pathway biomarkers such as IL22 and/or lipocalin-2 (LCN2).Type: ApplicationFiled: December 16, 2016Publication date: August 20, 2020Inventors: Robert W. Georgantas, III, Chris Morehouse, Brandon Higgs, Koustubh Ranade, Katie Streicher, William Rees, Meina Liang, Raffaella Faggioni, Jing Li, Inna Vainshtein, Yen-Wah Lee, Jinging Chen, Robert A. Gasser, JR.
-
Publication number: 20190338033Abstract: Provided herein are methods of treating B7-H1-expressing tumors comprising administering an effective amount of MEDI4736 or an antigen-binding fragment thereof.Type: ApplicationFiled: May 21, 2019Publication date: November 7, 2019Inventors: Rajesh Narwal, David Fairman, Paul Robbins, Meina Liang, Amy Schneider, Carlos Chavez, Carina Herl, Min Pak, Hong Lu, Marlon Rebelatto, Keith Steele, Anmarie Boutrin, Li Shi, Shengyan Hong, Brandon Higgs, Lorin Roskos
-
Publication number: 20190256603Abstract: Provided herein are methods of treating non-small cell lung cancers comprising administering an effective amount of durvalumab (MEDI4736) or an antigen-binding fragment thereof and tremelimumab or an antigen-binding fragment thereof. A combination of durvalumab and tremelimumab was effective at treating non-small cell lung cancers characterized as PD-L1- and having a high level of CD8+ tumor-infiltrating lymphocytes.Type: ApplicationFiled: November 10, 2017Publication date: August 22, 2019Inventors: KEITH STEELE, SONG WU, BRANDON HIGGS, MORITZ WIDMAIER, SONJA ALTHAMMER, RENE KORN, ANDREAS SPITZMUELLER
-
Patent number: 10336823Abstract: Provided herein are methods of treating B7-H1-expressing tumors comprising administering an effective amount of MEDI4736 or an antigen-binding fragment thereof.Type: GrantFiled: September 11, 2014Date of Patent: July 2, 2019Assignee: MedImmune LimitedInventors: Rajesh Narwal, David Fairman, Paul Robbins, Meina Liang, Amy Schneider, Carlos Chavez, Carina Herl, Min Pak, Hong Lu, Marlon Rebelatto, Keith Steele, Anmarie Boutrin, Li Shi, Shengyan Hong, Brandon Higgs, Lorin Roskos
-
Publication number: 20180364240Abstract: Provided herein are methods of treating a tumor comprising administering an effective amount of one or more immune-mediated cancer therapies, including durvalumab (MEDI4736) or an antigen-binding fragment thereof. Analysis of tumor sample sections using image analysis and gene expression identified patients for which immune-mediated cancer therapy would be effective. Durvalumab was effective at treating non-small cell lung cancers characterized by image analysis using tumor cell and immune cell markers (e.g., PD-Lq1 and CD8) and gene expression (e.g. IFN#).Type: ApplicationFiled: December 9, 2016Publication date: December 20, 2018Inventors: GERD BINNIG, SONJA ALTHAMMER, GUENTER SCHMIDT, BRANDON HIGGS, KEITH STEELE
-
Publication number: 20180282417Abstract: Disclosed are methods for treating cancer (e.g., solid tumor cancers, lung cancer, bladder head and neck cancer) with an anti-PD-L1 antibody in a patient identified as being responsive to anti-PD-L1 antibody therapy by detecting a mutation in one or more disclosed circulating tumor DNA (ctDNA) markers. Also disclosed are methods for determining the efficacy of anti-PD-L1 therapeutic antibody treatment in a patient having lung cancer or bladder cancer comprising detecting variant allele frequency in ctDNA in plasma samples and determining the difference of the variant allele frequency in ctDNA between the first and at least second plasma samples, wherein a decrease in the variant allele frequency in the at least second plasma sample relative to the first plasma sample identifies the anti-PD-L1 antibody treatment as effective.Type: ApplicationFiled: March 30, 2018Publication date: October 4, 2018Inventors: Brandon Higgs, Koustubh Ranade, Carlos Bais, Philip Brohawn, Michael Kuziora, Rajiv Raja
-
Publication number: 20180252728Abstract: The present invention relates to the use of components of the IL23 pathway as biomarkers, e.g., IL22, LCN2 and combinations thereof, to stratify or identify populations of patients suffering from IL23-mediated diseases (e.g., Crohn's disease) responsive to treatment with an anti-IL23 antagonist (including, e.g., anti-IL23 antibodies or antigen-binding fragments thereof). Levels of IL23 pathway biomarkers above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent (e.g., an ant-IL23 antibody), (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent.Type: ApplicationFiled: September 16, 2016Publication date: September 6, 2018Inventors: Robert W. Georgantas, III, Chris Morehouse, Brandon Higgs, Koustubh Ranade, Katie Streicher, William Rees, Meina Liang, Raffaella Faggioni, Jing Li, Inna Vainshtein, Yen-Wah Lee, Jingjing Chen, Robert A. Grasser, JR.
-
Publication number: 20170275347Abstract: The disclosure provides methods for treating lung cancer (e.g., non-small cell lung cancer) with an anti-PD-L1 antibody in a patient identified using a polynucleotide or polypeptide marker of the disclosure: CXCL9, KRT8, TRIM29, and/or IFNgamma.Type: ApplicationFiled: September 4, 2015Publication date: September 28, 2017Inventors: Brandon HIGGS, Jiaqi HUANG, Wei ZHU, Philip BROHAWN, Katie Streicher, Yihong YAO
-
Patent number: 9493570Abstract: The disclosure provides methods for treating a subject having a type I IFN-mediated disease or disorder comprising administration of a fixed does of an anti-interferon alpha receptor antibody. The disclosure also provides methods for suppressing a type I interferon (IFN) gene signature (GS) in a subject. In addition, the disclosure provides methods of prognosing or monitoring disease progression in a subject having a type I IFN-mediated disease or disorder, methods of predicting a dosage regimen, methods of identifying a candidate therapeutic agent, methods of identifying a patient as a candidate for a therapeutic agent, and methods of designating a personalized therapy.Type: GrantFiled: June 12, 2013Date of Patent: November 15, 2016Assignee: MedImmune, LLCInventors: Brandon Higgs, Yihong Yao, Bing Wang, Lorin Roskos, Linda Chang
-
Publication number: 20160222120Abstract: Provided herein are methods of treating B7-H1-expressing tumors comprising administering an effective amount of MEDI4736 or an antigen-binding fragment thereof.Type: ApplicationFiled: September 11, 2014Publication date: August 4, 2016Applicant: Medlmmune LimitedInventors: Rajesh Narwal, David Fairman, Paul Robbins, Meina Liang, Amy Schneider, Carlos Chavez, Carina Herl, Min Pak, Hong Lu, Marlon Rebelatto, Keith Steele, Anmarie Boutrin, Li Shi, Shengyan Hong, Brandon Higgs, Lorin Roskos
-
Publication number: 20160024205Abstract: The present disclosure encompasses type-I IFN and IFN?-induced PD marker expression profiles, kits, and methods for identifying such IFN?-induced PD marker expression profiles. The type-I IFN and IFN?-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFN?-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that modulates type 1 interferon activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFN? activity, and in diagnosing or providing a prognosis to patients having IFN?-induced disorders.Type: ApplicationFiled: October 6, 2015Publication date: January 28, 2016Applicant: MEDIMMUNE, LLCInventors: Brandon Higgs, Wei Zhu, Chris Morehouse, Barbara White, Bahija Jallal, Yihong Yao
-
Publication number: 20150191788Abstract: The present disclosure encompasses type-I IFN and IFN?-induced PD marker expression profiles, kits, and methods for identifying such IFN?-induced PD marker expression profiles. The type-I IFN and IFN?-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFN?-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that modulates type 1 interferon activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFN? activity, and in diagnosing or providing a prognosis to patients having IFN?-induced disorders.Type: ApplicationFiled: March 18, 2015Publication date: July 9, 2015Inventors: BRANDON HIGGS, WEI ZHU, CHRIS MOREHOUSE, BARBARA WHITE, BAHIJA JALLAL, YIHONG YAO